research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
Search
for
Sort by
Research
330-360 / 1000+ results 
research Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure.
A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
research Hyperandrogenism, Elevated 17-Hydroxyprogesterone and Its Urinary Metabolites in a Young Woman with Ovarian Steroid Cell Tumor, Not Otherwise Specified: Case Report and Review of the Literature
A young woman's symptoms suggested PCOS, but tests and surgery confirmed and treated a rare ovarian tumor, resolving her condition.
research Unveiling the Connection between Gut Microbiome and Polycystic Ovary Syndrome (PCOS)
PCOS is linked to gut bacteria changes, suggesting gut-focused treatments might help.
research Platelet-Rich Plasma and its Derivatives for Tissue Engineering
Platelet-rich plasma helps heal wounds and regenerate tissue in various medical fields.
research Dedifferentiation of committed epithelial cells into stem cells in vivo
Certain mature cells in mouse lungs can turn back into stem cells to aid in tissue repair.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research Uncovering the complex relationship between balding, testosterone and skin cancers in men
Men with baldness are more prone to skin cancers on the scalp due to sun exposure, not testosterone.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research The Cardiovascular Safety of Dutasteride
Dutasteride is as safe for the heart as finasteride.
research Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Disease Prevention and Alleviation by Human Myoblast Transplantation
Myoblast transplantation shows promise for treating various muscle and heart conditions.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Estimation of health utility values for alopecia areata
More severe hair loss in alopecia areata greatly impacts patients and caregivers.
research Pathologic Quiz Case: An 84-Year-Old Woman With a Skin Cyst Containing Ziehl-Neelsen–Positive Structures
Basal cell carcinoma may originate from vellus hair cysts.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients with Clinically Distinct Alopecia Areata Severity Profiles
Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.
research Perceived Stigma Among Adults With Alopecia Areata in the United States
Alopecia areata causes significant stigma and emotional distress, with many affected individuals not receiving adequate support or treatment.
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class Analysis
Vitiligo's impact varies widely, affecting both emotions and social life, not just physical symptoms.
research An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
Disease-specific tools better assess alopecia areata's impact on quality of life.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.